{
  "id": "b83fb080ce23a4d8",
  "title": "STAT+: Pharmalittle: We\u2019re reading about insurer spending on drugs, China\u2019s drug formulary and much more",
  "description": "And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter",
  "content": "And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter",
  "source": "STAT",
  "source_url": "https://www.statnews.com/pharmalot/2025/12/08/china-pfizer-jnj-lilly-glp1-dyne-kymera-recursion-mail/?utm_campaign=rss",
  "published_at": "2025-12-08T14:08:19+00:00",
  "fetched_at": "2025-12-09T00:22:19.510482+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug",
    "china"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Pharmalittle: We\u2019re reading about insurer spending on drugs, China\u2019s drug formulary and much more",
    "description": "And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter",
    "url": "https://www.statnews.com/pharmalot/2025/12/08/china-pfizer-jnj-lilly-glp1-dyne-kymera-recursion-mail/?utm_campaign=rss",
    "published": "2025-12-08T14:08:19+00:00",
    "source": "STAT"
  }
}